Assetmark Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Assetmark Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,980 shares of the biopharmaceutical company's stock after purchasing an additional 8,289 shares during the quarter. Assetmark Inc. owned 0.09% of Regeneron Pharmaceuticals worth $109,308,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 10 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of REGN stock traded up $3.94 during trading hours on Friday, reaching $828.42. The company's stock had a trading volume of 563,585 shares, compared to its average volume of 522,278. The stock has a market capitalization of $91.04 billion, a P/E ratio of 20.50, a P/E/G ratio of 3.12 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a one year low of $783.57 and a one year high of $1,211.20. The firm's fifty day simple moving average is $1,021.70 and its 200 day simple moving average is $1,036.38. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.48% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Leerink Partners reaffirmed a "market perform" rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Finally, TD Cowen raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,092.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.